Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1986;73:227-232

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fuster, V.
Right arrow Articles by Chesebro, J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fuster, V.
Right arrow Articles by Chesebro, J. H.

Circulation, Vol 73, 227-232, Copyright © 1986 by American Heart Association


ARTICLES

Role of platelets and platelet inhibitors in aortocoronary artery vein- graft disease

V Fuster and JH Chesebro

To study the prevention of occlusion of aortocoronary-artery bypass grafts, we conducted a prospective, randomized, double-blind trial comparing long-term administration of dipyridamole (begun 2 days before operation) plus aspirin (begun 7 hr after operation) with placebo in 407 patients. Results at 1 month and at 1 year showed a reduction in the rate of graft occlusion in patients receiving dipyridamole and aspirin. On the basis of our clinical trial and our experimental studies in dogs and pigs, we describe four consecutive phases of aortocoronary artery bypass vein-graft disease: an early postoperative phase of platelet thrombotic occlusion, which is significantly prevented by platelet inhibitor therapy when started in the perioperative period; in addition, occlusion rates are presently decreasing, perhaps related to better surgical and technical experience; an intermediate phase of platelet-related intimal hyperplasia, within the first postoperative year, which is not prevented with platelet inhibitor therapy; a late phase of occlusion, toward the end of the first postoperative year, in which intimal hyperplasia or complicating platelet thrombi superimposed on the intimal hyperplasia may contribute to occlusion; platelet inhibitor therapy is of significant benefit in the prevention of this thrombotic type of occlusion; a phase of atherosclerotic disease, after the first postoperative year, in which the role of platelets and of platelet inhibitor therapy is under investigation.


This article has been cited by other articles:


Home page
AMERICAN JOURNAL OF LIFESTYLE MEDICINEHome page
J. Hopkins and M. Limacher
The Role of Aspirin in Cardiovascular Disease Prevention in Women
American Journal of Lifestyle Medicine, March 1, 2009; 3(2): 123 - 134.
[Abstract] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
N. Zimmermann, E. Gams, and T. Hohlfeld
Aspirin in coronary artery bypass surgery: new aspects of and alternatives for an old antithrombotic agent.
Eur. J. Cardiothorac. Surg., July 1, 2008; 34(1): 93 - 108.
[Abstract] [Full Text] [PDF]


Home page
BMJHome page
E. Lim, Z. Ali, A. Ali, T. Routledge, L. Edmonds, D. G Altman, and S. Large
Indirect comparison meta-analysis of aspirin therapy after coronary surgery
BMJ, December 6, 2003; 327(7427): 1309.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
C. K. Chiu-Pinheiro, T. O'Brien, Z. S. Katusic, L. F. Bonilla, C. E. Hamner, and H. V. Schaff
Gene transfer to coronary artery bypass conduits
Ann. Thorac. Surg., October 1, 2002; 74(4): 1161 - 1166.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
M. R. Jackson and G. P. Clagett
Antithrombotic Therapy in Peripheral Arterial Occlusive Disease
Chest, January 1, 2001; 119 (2009): 283S - 299S.
[Full Text] [PDF]


Home page
CirculationHome page
E. H. Awtry and J. Loscalzo
Aspirin
Circulation, March 14, 2000; 101(10): 1206 - 1218.
[Full Text] [PDF]


Home page
CLIN APPL THROMB HEMOSTHome page
H. K. Breddin
Antiplatelet Agents in Cardiovascular and Cerebrovascular Diseases
Clinical and Applied Thrombosis/Hemostasis, April 1, 1998; 4(2): 87 - 95.
[Abstract] [PDF]


Home page
NEJMHome page
J.-P. Becquemin and The Etude de la Ticlopidineapres Pontage Femoro-Po
Effect of Ticlopidine on the Long-Term Patency of Saphenous-Vein Bypass Grafts in the Legs
N. Engl. J. Med., December 11, 1997; 337(24): 1726 - 1731.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. I. Weitz, J. Byrne, G. P. Clagett, M. E. Farkouh, J. M. Porter, D. L. Sackett, D. E. Strandness, and L. M. Taylor
Diagnosis and Treatment of Chronic Arterial Insufficiency of the Lower Extremities: A Critical Review
Circulation, December 1, 1996; 94(11): 3026 - 3049.
[Full Text]


Home page
Ann. Thorac. Surg.Home page
H. L. Dauerman, D. E. Cutlip, and F. W. Sellke
Intracoronary Thrombolysis in the Treatment of Graft Closure Immediately After CABG
Ann. Thorac. Surg., July 1, 1996; 62(1): 280 - 283.
[Abstract] [Full Text]


Home page
BMJHome page
Collaborative overview of randomised trials of antiplatelet therapy - II: Maintenance of vascular graft or arterial patency by antiplatelet therapy
BMJ, January 15, 1994; 308(6922): 159 - 168.
[Abstract] [Full Text]


Home page
PERSPECT VASC SURG ENDOVASC THERHome page
G. P. Clagett
Antithrombotic Drugs and Vascular Surgery
Perspectives in Vascular Surgery and Endovascular Therapy, January 1, 1990; 3(2): 79 - 102.
[PDF]